Tests tirzepatide before bariatric surgery in adults with obesity
Tests tirzepatide taken before weight-loss surgery in adults with obesity.
Key facts
- Who runs it
- Marlene Starr
- Where
- Lexington, United StatesSee the site
- Trial code
- Registry title
- 2024 Tirzepatide-Bariatric Surgery
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 50 people, planned
- Started
- 27 Mar 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- tirzepatide
- Standard of Care
- Record updated
- 14 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a BMI of 40 kg/m2 or more and an obesity-related health problem, who are scheduled for sleeve gastrectomy or gastric bypass surgery. It tests tirzepatide taken before the operation.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- BMI greater than or equal to 40 kg/m2 with one or more obesity-related comorbidities, planned for laparoscopic or robotic sleeve gastrectomy or gastric bypass surgery.
- Earlier treatment
- Must be enrolled in the weight loss surgery program at the UK HealthCare Weight Loss Surgery Clinic. Cannot have used a GLP-1 or GLP-1/GIP receptor agonist regularly in the past 90 days. Cannot have used immunosuppressive agents in the past 30 days.
- Biomarker or test result
- Must have no nicotine use, confirmed by serum nicotine and metabolite testing. Must be enrolled in the ADORE Bariatric Tissue Bank (IRB #69767).
Main reasons for not taking part
- Any reason not to use tirzepatide, such as allergy to it
- Personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasm syndrome type 2
- History of pancreatitis, or type 1 diabetes
- Diagnosed autoimmune disease
- Pregnant, breast-feeding, or planning pregnancy within 1 year after surgery
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- adults who have been enrolled in the multidisciplinary metabolic and bariatric surgery program at the UK HealthCare Weight Loss Surgery Clinic and are scheduled to receive laparoscopic or robotic sleeve gastrectomy, or gastric bypass surgery
- BMI greater than or equal to 40 kg/m2 with one or more obesity-related comorbidities
- have demonstrated abstinence from any form of nicotine use, confirmed by serum nicotine and metabolite testing
- enrollment in the ADORE Bariatric Tissue Bank (IRB #69767)
Who cannot take part
- female participant who is pregnant, breast-feeding, or intends to become pregnant with in 1 year following surgery
- Personal or family history of medullary thyroid carcinoma
- Patients with Multiple Endocrine Neoplasm syndrome type 2
- Hypersensitivity to tirzepatide
- History of pancreatitis
- Type 1 Diabetes
- diagnosed autoimmune disease
- moderate or severe substance use disorder according to DSM-5 criteria
- uncontrolled significant psychiatric disorder as assessed by specialized bariatric psychologist
- any contraindication to the use of tirzepatide (per package insert)
- patients with active, untreated or symptomatic cholelithiasis or jaundice
- consistent use of a GLP-1 or GLP-1/GIP receptor agonist, over the past 90 days
- current use of immunosuppressive agents or use within the past 30 days
- a prisoner
Where in United States
- University of KentuckyLexington, United StatesContact: Marlene Starr, PhDTaking people
About the trial
What the trial wants to find out
This clinical trial will test whether preoperative tirzepatide treatment improves outcomes after bariatric surgery. The outcome of this study could impact therapeutic guidelines for the multimodal treatment of obesity.
Read full original descriptionShow less
The major objectives are:
1. To evaluate whether pre-operative tirzepatide treatment reduces tissue and circulating inflammatory markers at the time of surgery. 2. To establish the relationship of these changes with postoperative improvements in weight loss, metabolic and inflammatory profiles, comorbidity resolution (glycemic control, blood pressure, lipid profile), and 30-day surgical complications. Researchers will compare data from patients taking tirzepatide to data from patients not taking tirzepatide before their planned bariatric surgery to see if tirzepatide reduces inflammation and improves health outcomes after bariatric surgery.
Participants will:
Take or not take tirzepatide, depending on what study group they are in, once a week for 3 months.
Visit the endocrine clinic once a month for 3 months to be prescribed the drug and for checkups regarding side effects due to the drug.
Keep a diary to document taking the drug and any side effects. Continue with their planned bariatric surgery and post-surgery follow-ups according to their healthcare provider.
The 2 groups in the trial
- Standard of Care plus DrugTreatment being tested
Participant receives drug for 3 months prior to surgery
Treatment: tirzepatide
- Standard of Care AloneExisting treatment, for comparison
Treatment: Standard of Care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Preoperative Tirzepatide for Bariatric Surgery
- Plain-language title
- Tests tirzepatide before bariatric surgery in adults with obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 14 May 2026